Tango Therapeutics, Inc. (TNGX), headquartered in Cambridge, Massachusetts, is devoted to unraveling cancer's complexity and overcoming its resistance to treatment. This biotechnology company specializes in pioneering the discovery, development, and commercialization of innovative medicines that can improve and potentially prolong the lives of people suffering from cancer. Tango Therapeutics is driven by its purpose of altering the paradigm of cancer therapies to revolutionize patient care.
Founded in 2017 by leading scientists from renowned science and research entities, the company is primarily focused on creating medicines that exploit cancer's vulnerabilities. Tango Therapeutics' uniqueness lies in its proprietary research platform that leverages advances in DNA sequencing and CRISPR-based functional genomics to uncover genetically validated therapeutic targets.
Through this platform, the company aims to create superior, more precise, and individualized treatments for patients with a variety of cancer types. The company has meticulously integrated drug discovery capabilities to help accelerate the development and launch of their first program into clinical trials.
Tango Therapeutics is presently focused on developing targeted therapies for patients suffering from genetically defined cancers. They maintain a patient-centric approach, leaning on genetic data to design treatments that maximize effectiveness and minimize side effects. Their pipeline includes potential solutions for various types of cancer, including BRCA-1 breast cancer, CDK12 prostate cancer, and others still in the early phases of discovery and development.
Tango is unique due to its “synthetic lethality” method, a technique that detects and utilizes the interactions between pairs of genes in which the defect or disorder in one gene is harmless unless a corresponding defect occurs in the other gene. This approach offers the potential for targeted cancer therapies that could outperform traditional methods.
Tango Therapeutics' pioneering work in synthetic lethality and genetic vulnerabilities has attracted significant interest and support from high-profile institutional investors and industry partners. It's financed by Third Rock Ventures, Boxer Capital, and Casdin Capital, among others.
Tango Therapeutics, Inc. exemplifies how the integration of cutting-edge technology and a deep understanding of genomics can produce pioneering remedies to some of the most challenging health problems. With a mission built on science, innovation, and determination, this young biotech company shows immense promise in ushering in a new era of personalized cancer treatment.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Trv Gp Iv LLC has significantly invested in Tango Therapeutics, Inc. (NASDAQ:TNGX) by acquiring over 6.37 million shares, making it their second-largest holding. This investment, valued at approximately $120 billion, represents about 4.41% of Tango Therapeutics. Despite the company missing its recent quarterly EPS estimates, analyst sentiment remains largely positive, with a "Moderate Buy" consensus rating and an average price target of $43.46.
Trv Gp Vi LLC has acquired a new stake in Tango Therapeutics, Inc. (NASDAQ:TNGX), purchasing 194,174 shares valued at approximately $6.07 billion, making it their 4th largest position. The article highlights other institutional investments, insider selling, and current analyst ratings, which show a consensus "Moderate Buy" with an average price target of $43.46 despite a recent earnings miss. Tango Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for cancer.
H.C. Wainwright has increased its target price for Tango Therapeutics, Inc. (TNGX.O) from $66 to $68. This update reflects a positive adjustment in the firm's outlook for the biotechnology company. The news was reported by Reuters.
Tango Therapeutics recently announced a wider net loss, a $400 million at-the-market equity offering, and leadership changes aimed at bolstering its commercialization efforts. These strategic moves suggest the company is preparing vopimetostat for late-stage development and commercial launch, though they also highlight potential shareholder dilution. The stock's current valuation already reflects high expectations despite the company's distant profitability.
HC Wainwright has increased its price target for Tango Therapeutics (NASDAQ:TNGX) to $68.00 from $66.00, maintaining a "buy" rating and suggesting a significant upside. This comes despite the company reporting a quarterly loss of $0.37 per share, missing the consensus estimate. Tango Therapeutics currently holds a "Moderate Buy" consensus rating from analysts, with an average price target of $43.46.